Department of Pharmacology, University of Cape Town, South Africa.
Tuberculosis (Edinb). 2009 Dec;89 Suppl 1(Suppl 1):S33-40. doi: 10.1016/S1472-9792(09)70009-5.
Artemisia afra [Jacq] (Asteraceae) phytotherapy is widely used for its medicinal properties in traditional practices. In this study we investigated whether extracts of A. afra are capable of controlling mycobacterial replication. For Mycobacterium aurum cultured in the presence of aqueous-, methanol- and dichloromethane (DCM) extracts of A. afra we found that bacterial replication was inhibited by the dichloromethane extract only. Activity of the DCM extract was confirmed in dose-dependent studies against both M. aurum and M. tuberculosis with an IC(50) =270 microg/ml and IC(50) = 290microg/ml, respectively. Fractionation of the DCM extract and evaluation of its efficacy in vitro found that most of the antimycobacterial activity was associated with isolate fraction C8 that contained several sesquiterpene lactones, the most prominent of which are Artemin and Arsubin. Evaluation of the bactericidal efficacy in vitro showed that isolate fraction C8 reduced replication of M. aurum and M. tuberculosis in a dose-dependent manner with IC(50) =1.9 microg/ml and IC(50) = 2.0 microg/ml, respectively, and an MIC = 10 microg/ml. Further, isolate fraction C8 and the DCM extract was administered to M. tuberculosis-infected mice at a tolerated dose of 1000 microg/kg for up to 26 weeks and mycobacterial burdens compared to untreated-, INH/RIF treated- and aqueous-extract-treated animals to assess its bactericidal activity in vivo. Bacterial replication remained unaffected during treatment with either isolate fraction C8 or the DCM extract resulting in pulmonary and splenic bacilli burdens comparable to that of untreated mice. In contrast, INH/RIF treatment cleared M. tuberculosis infection after only 8 weeks to undetectable levels. Interestingly, treatment of M. tuberculosis-infected mice with aqueous extract of A. afra regulated pulmonary inflammation during early infection notwithstanding its inability to inhibit mycobacterial growth. This study clearly demonstrates that A. afra contains in vitro anti-mycobacterial activity, modulates pulmonary inflammation in early mycobacterial infection, and that the mouse experimental tuberculosis model may serve as a useful assay for evaluating the utility of phytotherapy.
非洲蒿(Asteraceae)的植物疗法因其药用特性在传统实践中被广泛应用。在这项研究中,我们研究了非洲蒿的提取物是否具有控制分枝杆菌复制的能力。对于在含有非洲蒿的水提物、甲醇提物和二氯甲烷(DCM)提物中培养的金黄分枝杆菌,我们发现只有 DCM 提取物能抑制细菌的复制。在针对金黄分枝杆菌和结核分枝杆菌的剂量依赖性研究中,DCM 提取物的活性得到了证实,其 IC50 值分别为 270μg/ml 和 290μg/ml。DCM 提取物的分级分离及其体外功效评估发现,大多数抗分枝杆菌活性与包含几种倍半萜内酯的分离物 C8 有关,其中最主要的是 Artemin 和 Arsubin。体外杀菌功效评估表明,分离物 C8 以剂量依赖性方式降低金黄分枝杆菌和结核分枝杆菌的复制,其 IC50 值分别为 1.9μg/ml 和 2.0μg/ml,MIC 值为 10μg/ml。此外,分离物 C8 和 DCM 提取物以耐受剂量 1000μg/kg 给予结核分枝杆菌感染的小鼠,直至 26 周,然后与未处理组、INH/RIF 处理组和水提物处理组比较,以评估其体内的杀菌活性。无论是用分离物 C8 还是 DCM 提取物处理,分枝杆菌的复制都没有受到影响,导致肺部和脾脏的细菌负荷与未处理的小鼠相当。相比之下,INH/RIF 治疗仅在 8 周后即可清除结核分枝杆菌感染,使其降至无法检测的水平。有趣的是,即使不能抑制分枝杆菌的生长,用非洲蒿的水提物治疗结核分枝杆菌感染的小鼠也能在早期感染时调节肺部炎症。本研究清楚地表明,非洲蒿含有体外抗分枝杆菌活性,能调节早期分枝杆菌感染中的肺部炎症,而且小鼠实验性结核模型可作为评估植物疗法实用性的有用检测方法。